Company intelligence / Profile preview
DNAtrix
San Diego, California, United Statesdnatrix.com ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Other
01
Overview
DNAtrix has demonstrated promising early clinical results with its lead candidate DNX‑2401 in recurrent glioblastoma. The product has received FDA Fast Track and Rare Pediatric Disease designations. Additional candidates are advancing through early-stage clinical trials targeting a range of solid tumors and metastatic cancers.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Oncolytic viruses (engineered adenovirus platform)Gene therapy
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on DNAtrix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNAtrix.